Program
brexanolone
Also written as “SAGE-547”, “Brexanolone” and “LPCN 1154A”.
Its studies are mostly in Depression, Postpartum · Status Epilepticus · Tinnitus · Respiratory Distress Syndrome · Essential Tremor, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Supernus Pharmaceuticals | 120 open or running | phase 4since Feb 14, 2020 | Jan 28, 2014 | none ahead |
| Lipocine | 21 open or running | phase 3since May 13, 2025 | May 13, 2025 | Aug 2027phase 3 · NCT07822321 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 28, 2014First study: phase 2 study in Status EpilepticusNew to Supernus PharmaceuticalsSupernus Pharmaceuticals · NCT02052739 · 25 enrolled · United States
- Oct 22, 20142 phase 2 studiesSupernus Pharmaceuticals · NCT02285504, NCT02277106
- Jun 2, 2015Phase 3 study in Super-Refractory Status EpilepticusSupernus Pharmaceuticals · NCT02477618 · 132 enrolled · United States, Austria, Canada and more
- Nov 2, 2015Phase 2 study in Depression, PostpartumSupernus Pharmaceuticals · NCT02614547 · 21 enrolled · United States
- Oct 20, 20162 phase 3 studies in Depression, PostpartumSupernus Pharmaceuticals · NCT02942017, NCT02942004
- Apr 30, 2018Phase 3 study in Depression, PostpartumSupernus Pharmaceuticals · NCT03665038 · 28 enrolled · United States
- Feb 14, 2020Phase 4 study in Depression, PostpartumSupernus Pharmaceuticals · NCT04273191
- Sep 1, 2020Phase 3 study in Respiratory Distress SyndromeSupernus Pharmaceuticals · NCT04537806 · 29 enrolled · United States
- Sep 17, 2021Phase 4 study in Depression, PostpartumSupernus Pharmaceuticals · NCT05059600 · 52 enrolled · United States
- Dec 1, 2022Phase 2 study in TinnitusSupernus Pharmaceuticals · NCT05645432 · 10 enrolled · United States
- May 13, 2025Lipocine's first study: phase 3 study in Depression, PostpartumNew to LipocineLipocine · NCT06979544 · 90 enrolled · United States
- Sep 10, 2026Phase 3 study in Depression, PostpartumLipocine · NCT07822321 · 120 planned · United States
Ahead
- Aug 2027Primary completion: phase 3 study in Depression, PostpartumLipocine · NCT07822321
TargetBeta
“GABA-A receptor; anion channel positive allosteric modulator”ChEMBL 37, by rule
Other programs on the same 16 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Midazolamrule | Pfizer | phase 4 | 96 |
| ciprofolrule | Haisco Pharmaceutical Group | phase 4 | 36 |
| Alprazolamrule | Viatris | phase 4 | 35 |
| Diazepamrule | Acorda Therapeutics | phase 3 | 9 |
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07822321Depression, Postpartum · United States | 3 | Recruiting | Lipocine | Aug 2027 | 120 |
| NCT06979544Depression, Postpartum · United States | 3 | Completed | Lipocine | Jan 16, 2026 | 90 |
| NCT05645432Tinnitus · United States | 2 | Completed | Supernus Pharmaceuticals | Nov 21, 2023 | 10 |
| NCT05059600Depression, Postpartum · United States | 4 | Completed | Supernus Pharmaceuticals | Jul 14, 2022 | 52 |
| NCT04537806Respiratory Distress Syndrome · United States | 3 | Terminated | Supernus Pharmaceuticals | Jul 1, 2021 | 29 |
| NCT04273191Depression, Postpartum | 4 | Withdrawn | Supernus Pharmaceuticals | Aug 2021 | 0 |
| NCT03665038Depression, Postpartum · United States | 3 | Completed | Supernus Pharmaceuticals | Jan 8, 2021 | 28 |
| NCT02942017Depression, Postpartum · United States | 3 | Completed | Supernus Pharmaceuticals | Sep 17, 2017 | 108 |
| NCT02942004Depression, Postpartum · United States | 3 | Completed | Supernus Pharmaceuticals | Sep 24, 2017 | 138 |
| NCT02614547Depression, Postpartum · United States | 2 | Completed | Supernus Pharmaceuticals | Jun 22, 2016 | 21 |
| NCT02477618Super-Refractory Status Epilepticus · United States, Austria, Canada and more | 3 | Completed | Supernus Pharmaceuticals | Jul 18, 2017 | 132 |
| NCT02285504Depression, Postpartum · United States | 2 | Completed | Supernus Pharmaceuticals | Jun 5, 2015 | 4 |
| NCT02277106Essential Tremor · United States | 2 | Completed | Supernus Pharmaceuticals | Aug 14, 2015 | 25 |
| NCT02052739Status Epilepticus · United States | 2 | Completed | Supernus Pharmaceuticals | May 3, 2015 | 25 |
How it is read
Names in the registry
- “SAGE-547”, 5 entries
- “Brexanolone”, 4 entries
- “LPCN 1154A”, 2 entries
- “SAGE-547 90 μg/kg/h”, 2 entries
- “SAGE-547 60 μg/kg/h”, 1 entry
Conditions, from the studies’ own filings
- Depression, Postpartum, 9 studies
- Status Epilepticus, 2 studies
- Tinnitus, 1 study
- Respiratory Distress Syndrome, 1 study
- Essential Tremor, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.